Author Login

Correspondence to Author: Elesis Vaass, 

Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, 110 avenue des Pins Ouest, Montreal, Québec, Canada, H2W 1R7.

ABSTRACT: 
Context : Apolipoprotein E malfunction caused by a genetic mutation in combination with other metabolic variables results in residual lipoproteins building up in the plasma, a condition known as dysbetalipoproteinemia (DBL). An elevated risk of peripheral vascular disease and coronary heart disease (PVD) has been noted in these patients in research conducted in the past. Comparing the incidence of PVD and atherosclerotic cardiovascular disease (ASCVD) in a cohort of patients with DBL to normolipidemic controls was the main goal of the study. The incidence of PVD and ASCVD was compared between individuals with familial hypercholesterolemia (FH) and patients with DBL as a secondary goal.
Methods : The study comprised 1481 normolipidemic controls, 725 patients with FH, and 221 patients with DBL. Medical records were examined in order to gather the data.
Results : Compared to normolipidemic controls, patients with DBL had an overall increased risk of PVD (hazard ratio [HR] 13.58, 95% CI 4.76-38.75) and ASCVD (HR 3.55, 95% CI 2.17-5.83) (P.0001). Patients with DBL showed an elevated risk of PVD (HR 3.89, 95% CI 1.20-12.55, P=.02) in comparison to those with FH.
conclusion : we showed that compared to normolipidemic controls, DBL patients have >3-fold and >13-fold greater risks of ASCVD and PVD, respectively. Moreover, DBL has a roughly 4-fold higher risk of PVD than FH. In order to enhance the clinical management of these patients by halting the progression of ASCVD, adequate DBL screening is essential.

Citation:

Elesis Vaass. An Increased Risk of Coronary and Peripheral Vascular Disease Is Associated With Dysbetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism 2024.